Idexx Labs (IDXX) Tops Q3 EPS by 1c; Raises FY11 Outlook; Guides FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts IDXX Hot Sheet
Price: $553.48 -0.8%
Revenue Growth %: +8.2%
Financial Fact:
Income before provision for income taxes: 81.52M
Today's EPS Names:
CFFI, ZGN, SSNC, More
Revenue Growth %: +8.2%
Financial Fact:
Income before provision for income taxes: 81.52M
Today's EPS Names:
CFFI, ZGN, SSNC, More
Join SI Premium – FREE
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q3 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $301 million versus the consensus estimate of $294.88 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.71-$2.74, versus prior guidance of $2.68-$2.73 and the consensus of $2.72. Idexx Laboratories, Inc. sees FY2011 revenue of $1.215 billion, versus prior guidance of $1.205-$1.215 billion and the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2012 EPS of $3.00-$3.10, versus the consensus of $3.06. Idexx Laboratories, Inc. sees FY2012 revenue of $1.295-$1.315 billion, versus the consensus of $1.30 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- Qiagen posts $548M in Q3 2026 net sales amid pending EQT deal
- Wyndham Hotels & Resorts, Inc. (WH) Tops Q3 EPS by 12c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
